Skip to main content

Table 1 The characteristics of included trials

From: Glucagon-like peptide-1 (GLP-1) receptor agonists and cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of double-blind, randomized, placebo-controlled clinical trials

Study Country of publication Country of patients Experimental Sample size Control Sample Size Age Duration of diabetes Intensive Therapy Control therapy Follow-up
Adrian F Hernandez 2018 [10] USA Western Europe
Eastern and central Europe
North America
Latin America
Asia Pacific
4731 4732 64.2/
64.2
4.1/
4.2
Albiglutide
(30-50mg) once a week
Placebo once a week 1.5 years
Rury R. Holman 2017 [4] United Kingdom Europe,
Latin America
Europen subcategories,
Asia-pacific,
Eastern Europe,
Western Europe, North America
7356 7396 <65y
8813
≥65y
5939
12.0
(7.0-18.0)
exenatide at a dose of 2 mg once weekly Placebo once a week 2.3 years
Steven P2016 [7] USA North AmericaEurope Asia
Rest of the world
4668 4672 <60y 2321
≥60y
7019
12.8 years liraglutide 1.8 mg (or the maximum tolerated dose) once daily placebo once daily 3.8 years
Steven P. Marso2016 [8] United Kingdom 230 sites in 20 countries. 1648 1649 64.6±
7.4
13.9±
8.1
semaglutide (0.5mg or
1.0mg) once a week
Placebo once a week 109 weeks
Preffer MA 2015 [3] Thailand 49 countrirs 3034 3034 60.3 9.3 lixisenatide placebo 2.1 years
Gerstein HC 2019 [9] UK 371 sites
24 countries
4949 4952 66.2 10.5/
9.5
dulaglutide 1.5mg placebo 5.4 years